| Literature DB >> 30614526 |
Laura Mary1,2, Kirsley Chennen2,3, Corinne Stoetzel2, Manuela Antin1, Anne Leuvrey1, Elsa Nourisson1, Elisabeth Alanio-Detton4, Maria C Antal5,6, Tania Attié-Bitach7,8, Patrice Bouvagnet9, Raymonde Bouvier10, Annie Buenerd10, Alix Clémenson11, Louise Devisme12, Bernard Gasser13, Brigitte Gilbert-Dussardier14,15, Fabien Guimiot16, Philippe Khau Van Kien17, Brigitte Leroy18, Philippe Loget19, Jelena Martinovic20, Fanny Pelluard21,22, Marie-Josée Perez23, Florence Petit24, Lucile Pinson25, Caroline Rooryck-Thambo26, Olivier Poch3, Hélène Dollfus2,27,28, Elise Schaefer2,27, Jean Muller1,2.
Abstract
Bardet-Biedl syndrome (BBS) is an emblematic ciliopathy associated with retinal dystrophy, obesity, postaxial polydactyly, learning disabilities, hypogonadism and renal dysfunction. Before birth, enlarged/cystic kidneys as well as polydactyly are the hallmark signs of BBS to consider in absence of familial history. However, these findings are not specific to BBS, raising the problem of differential diagnoses and prognosis. Molecular diagnosis during pregnancies remains a timely challenge for this heterogeneous disease (22 known genes). We report here the largest cohort of BBS fetuses to better characterize the antenatal presentation. Prenatal ultrasound (US) and/or autopsy data from 74 fetuses with putative BBS diagnosis were collected out of which molecular diagnosis was established in 51 cases, mainly in BBS genes (45 cases) following the classical gene distribution, but also in other ciliopathy genes (6 cases). Based on this, an updated diagnostic decision tree is proposed. No genotype/phenotype correlation could be established but postaxial polydactyly (82%) and renal cysts (78%) were the most prevalent symptoms. However, autopsy revealed polydactyly that was missed by prenatal US in 55% of the cases. Polydactyly must be carefully looked for in pregnancies with apparently isolated renal anomalies in fetuses.Entities:
Keywords: BBS; Bardet-Biedl syndrome; antenatal presentation; diagnostic strategy
Year: 2019 PMID: 30614526 DOI: 10.1111/cge.13500
Source DB: PubMed Journal: Clin Genet ISSN: 0009-9163 Impact factor: 4.438